SVA — Sinovac Biotech Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.74% | ||
| Return on Equity | -1.51% | ||
| Operating Margin | -103.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 246.05 | 510.62 | 19,374.9 | 1,492.76 | 448.27 | n/a | n/a | 14.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +8.68 | +151.66 | +7974.01 | -98.69 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sinovac Biotech Ltd (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, hand foot and mouth disease (HFMD), seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine.
Directors
- WeiDong Yin CHM (57)
- Nan Wang CFO (54)
- Qiang Gao COO (44)
- Jing Li VPR (47)
- Simon Anderson IND (59)
- Shan Fu IND (54)
- Kenneth Lee IND (52)
- Yuk Lam Lo IND (71)
- Meng Mei IND (66)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 1st, 1999
- Public Since
- November 13th, 2009
- No. of Employees
- 3,037
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 99,638,043
- Address
- No. 39 Shangdi Xi Road, Haidian District, BEIJING, 100085
- Web
- http://www.sinovac.com/
- Phone
- +86 1082890088
- Contact
- Guang Yang
- Auditors
- GRANT THORNTON ZHITONG CERTIFIED PUBLIC ACCOUNTANTS LLP
Upcoming Events for SVA
Similar to SVA
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 23:16 UTC, shares in Sinovac Biotech are trading at $6.47. This share price information is delayed by 15 minutes.
Shares in Sinovac Biotech last closed at $6.47 and the price had moved by -20.32% over the past 365 days. In terms of relative price strength the Sinovac Biotech share price has underperformed the S&P500 Index by -26.45% over the past year.
There is no consensus recommendation for this security.
Find out moreSinovac Biotech does not currently pay a dividend.
Sinovac Biotech does not currently pay a dividend.
Sinovac Biotech does not currently pay a dividend.
To buy shares in Sinovac Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.47, shares in Sinovac Biotech had a market capitalisation of .
Here are the trading details for Sinovac Biotech:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SVA
Based on an overall assessment of its quality, value and momentum Sinovac Biotech is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinovac Biotech. Over the past six months, its share price has outperformed the S&P500 Index by +8.1%.
As of the last closing price of $6.47, shares in Sinovac Biotech were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sinovac Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sinovac Biotech's management team is headed by:
- WeiDong Yin - CHM
- Nan Wang - CFO
- Qiang Gao - COO
- Jing Li - VPR
- Simon Anderson - IND
- Shan Fu - IND
- Kenneth Lee - IND
- Yuk Lam Lo - IND
- Meng Mei - IND